MedTrace Logo

Phase II Study With Hiltonol and Dendritic Cells in Solid Tumors

NCT01734564 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2017-04-11

No results posted yet for this study

Summary

In this phase II study, patients with solid tumors will receive treatment with hiltonol and autologous dendritic cells.

Conditions

  • Neoplasms

Interventions

BIOLOGICAL

Hiltonol and autologous dendritic cells

Hiltonol and autologous dendritic cells

RADIATION

Hiltonol, dendritic cells and radiation

Hiltonol, autologous dendritic cells and radiation therapy. Radiation therapy will pursue an abscopal effect.

Sponsors & Collaborators

  • Clinica Universidad de Navarra, Universidad de Navarra

    lead OTHER

Principal Investigators

  • Jose Luis Perez Gracia, MD, PhD · Clinica Universidad de Navarra

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2016-12-31
Completion
2016-12-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01734564 on ClinicalTrials.gov